<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654249</url>
  </required_header>
  <id_info>
    <org_study_id>THD_LIGA_RCT</org_study_id>
    <nct_id>NCT02654249</nct_id>
  </id_info>
  <brief_title>Prospective Randomized Trial About THD Versus Ligasure Hemorrhoidectomy for Grade III and IV Hemorrhoids</brief_title>
  <acronym>THD-LIGA</acronym>
  <official_title>Prospective Multicenter Randomized Trial About Transanal Hemorrhoidal Dearterialization With Mucopexy (THD) Versus Ligasure Hemorrhoidectomy for Grade III and IV Hemorrhoids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates postoperative pain, morbidity, recurrence and quality of life, comparing
      two different strategies in the treatment of grade III and IV hemorrhoids: transanal
      hemorrhoidal dearterialization with mucopexy (THD) versus hemorrhoidectomy by Ligasure™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transanal hemorrhoidal dearterialization (THD)‪ uses a specially developed anoscope combined
      with a Doppler transducer to identify the hemorrhoidal arteries. A suture ligation is
      performed to effectively decrease the blood flow to the hemorrhoidal plexus. In case of
      redundant prolapse, the prolapsed mucosa is lifted (mucopexy). THD procedure is performed
      without any incisions or removal of the hemorrhoidal tissue and moreover the suture line is
      above the dentate line, so post-operative pain and morbidities seem to be minimized in these
      patients. This technique differs from Ligasure hemorrhoidectomy, which focuses on excising
      the hemorrhoidal tissue.

      This prospective, randomized, multicenter and controlled trial compares post-operative pain,
      morbidities, quality of life, fecal incontinence and recurrence rate in patients treated for
      grade III and IV hemorrhoids with THD with mucopexy versus Ligasure hemorrhoidectomy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative pain</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
    <description>Post-operative pain by simple verbal numerical scale (0-10), the Andersen scale (0-5) and the taken pain medicacions will be recorded by the patients on a specific book during the first thirty days after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At 1 month and at 1 and 2 years after surgery</time_frame>
    <description>Quality of life by Short Form 12 (SF-12) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific disabilities (fecal incontinence and costipation)</measure>
    <time_frame>At the day 15, 30 and at 1 and 2 years after surgery</time_frame>
    <description>Fecal incontinence by Vaizey Score and need of laxatives. Anorecatal manometry and endoanal ultrasonography will be performed two month after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative morbidity</measure>
    <time_frame>within the first 30 days after surgery</time_frame>
    <description>Dindo classification of complicacions will be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhoid recurrence</measure>
    <time_frame>At 1 and 2 years after surgery</time_frame>
    <description>rectal bleeding, anal pain, mucosal prolaps will be invastigated one year after hemorroidectomy. Needing of further surgery for hemorrhoids recurrence will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction after surgery</measure>
    <time_frame>At the day 15, 30 and at 1 and 2 years after surgery</time_frame>
    <description>A scale of 0-3 (0, not satisfied; 1 few satisfied, 2 satisfied, 3, very satisfied) will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hemorrhoids</condition>
  <arm_group>
    <arm_group_label>THD and mucopexy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will undergo to transanal hemorrhoidal dearterialization with mucopexy (THD)‪ under generla anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ligasure hemorroidectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will undergo to Ligasure™ hemorroidectomy under generla anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transanal hemorrhoidal dearterialization + mucopexy (THD).</intervention_name>
    <description>Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.</description>
    <arm_group_label>THD and mucopexy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ligasure™ hemorrhoidectomy</intervention_name>
    <description>Excisional hemorroidectomy performed with Ligasure™</description>
    <arm_group_label>Ligasure hemorroidectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>THD anoscope and doppler</intervention_name>
    <description>An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure</description>
    <arm_group_label>THD and mucopexy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ligasure Vessel Sealing</intervention_name>
    <description>A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy</description>
    <arm_group_label>Ligasure hemorroidectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with grade III and IV hemorrhoids according to Goligher classification

          -  Patients ASA I, II or III and adequate hematological, renal and hepatic function

          -  Patients who signed informed consent

        Exclusion Criteria:

          -  Altered cognitive state that prevents collaboration in the study or patients who can
             neither read nor write

          -  Fecal incontinence

          -  Anal sphincter lesions

          -  Recurrent hemorrhoids after previous surgical tratment

          -  Previous anorectal surgery except banding, botulinum toxin injection and thrombectomy
             for hemorrhoid thrombosis

          -  Injection sclerotherapy during the last five years

          -  Concomitant anorectal disease (anal fistula, anal fissure, anal stenosis, rectocele,
             enterocele, anal condilomatosis).

          -  Concomitant diagnosis of functional pelvic floor disease, inflammatory bowel disease
             and previous pelvic radiotherapy

          -  Concomitant diagnosis of colorectal neoplasia or other neoplasia

          -  Patients ASA IV, V

          -  NSAIDs, Paracetamol, Tramadol, Metamizol and Petidine allergy

          -  Coagulation disorders

          -  Pregnancy and lactation

          -  Rejection of the patient to sign the consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastiano Biondo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bellvitge University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellvitge University Hospital</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rey Juan Carlos</name>
      <address>
        <city>Mostoles</city>
        <state>Madrid</state>
        <zip>28933</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal de Valdeorras</name>
      <address>
        <city>O Barco de Valdeorras</city>
        <state>Ourense</state>
        <zip>32300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galdakano Usansolo Hospital</name>
      <address>
        <city>Bizkaia</city>
        <state>Pais Vasco</state>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Ribera</name>
      <address>
        <city>Alzira</city>
        <state>Valencia</state>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valle d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Leon</name>
      <address>
        <city>Leon</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Sebastiano Biondo</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Hemorrhoids grade III and IV</keyword>
  <keyword>transanal hemorrhoidal dearterialization</keyword>
  <keyword>hemorroidectomy</keyword>
  <keyword>THD</keyword>
  <keyword>LigaSure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhoids</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

